Links

Homepage

Stock List

Search by Ticker

News

Login

Horizon Therapeutics Public Lim (NASDAQ:HZNP)
Stock Analysis

HZNP109.14
▼ -0.09%-0.1

Stock Analysis

The following stock analysis is based on 10.7 years of data (i.e. since Jul 23, 2012). All the stock history has been downloaded.

Stock Exchange

Horizon Therapeutics Public Lim trades on the NasdaqGS exchange in USD dollars.

Sector

It is in the healthcare sector.

Current Status of Horizon Therapeutics Public Lim

It is currently trading at $109.14 ($109.24 the previous day).

Financials

The next reporting date is in 39 days (2023 05 10).

CNN estimates profits for the upcoming quarter will be $1.16 per share ($904.3M). The current Canada / US exchange rate is 1.3511.



Over the past 12 months, $49669 worth of shares have been purchased and $80406677 worth of shares have been sold by insiders.

Will This Trend Continue?

The year over year average increase is 51.0% per year assuming steady exponential growth. The actual 5 year average is 53.52. Details on the individual increase in one year intervals is provided below.

Past PerformanceAverage PricePercent Change
1 year90.504616788321-8.9- Below Average
2 year99.39344012738948.8- Below Average
3 year66.795880536913141.2+ Above Average
4 year27.69792536231940.6- Below Average
5 year19.70292775665445.9- Below Average
Horizon Therapeutics Public Lim is projected by analysts to get to $116.50 within the next 12 months (6.7%), but preticted targets range from as high as $116.50 (6.7%) and as low as $116(6.3%).

Risk

The worst drop it has had in recent years is -74.9%. It has a few bumps shape to the stock curve, which means the stock generally continues on a consistent trend and does not have to be checked often, but can have some variation during periods of volitility.

Stock shape test

DAYS AG0PRICE
10110.04DROPPING
30109.93RISING
60113.03DROPPING
15065.12RISING
365109.38DROPPING
80078.73RISING
120032.25RISING
160022.09RISING
200013.67RISING


With an average increase of 51.0% year over year, if Horizon Therapeutics Public Lim is bought at the worst time, Stockmarketizer analysts estimate it will take 17.6 months before the stock will recover to the original purchase price. The P/E value is 49.38. The stock is under valued as the industry standard in the healthcare sector is a P/E of 86.26.

Tradingview BuySell Widget

Yahoo News Feed

Should You Invest in Horizon Therapeutics Public Limited Company (HZNP)?

Thu, 23 Mar 2023 07:09:54 Renaissance Investment Management, an investment management company, released its “Midcap Growth Strategy” fourth-quarter investor letter. A copy of the same can be downloaded here. In the fourth quarter, the strategy returned 11.23% (net) compared to a 6.90% return for the Russell Midcap ...... Read Full Article

Here's Why Horizon Therapeutics (HZNP) is a Strong Growth Stock

Fri, 17 Mar 2023 13:45:01 The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.... Read Full Article

Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)

Thu, 16 Mar 2023 15:55:00 DUBLIN, March 16, 2023--Horizon Therapeutics plc (NASDAQ: HZNP):... Read Full Article

New Analysis of MRI Findings Show UPLIZNA® (inebilizumab-cdon) Reduced the Formation of Asymptomatic Optic Nerve Lesions in People With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Tue, 14 Mar 2023 15:15:00 DUBLIN, March 14, 2023--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of new MRI imaging data from the Phase 3 clinical trial showing UPLIZNA reduced the formation of subclinical (asymptomatic) optic nerve lesions in people with NMOSD. These findings are being ...... Read Full Article

Real-World Experience Shows TEPEZZA® (teprotumumab-trbw) Was Effective in Treating People With Dysthyroid Optic Neuropathy (DON)

Sun, 12 Mar 2023 16:00:00 DUBLIN, March 12, 2023--Horizon Therapeutics announced new data on the use of TEPEZZA (teprotumumab-trbw) in patients with dysthyroid optic neuropathy (DON) at NANOS 2023.... Read Full Article

7 Over-$100 Stocks That Are Worth Every Penny

Fri, 03 Mar 2023 11:30:17 If searching out over-$100 stocks to buy seems arbitrary, take a step back and consider this. It’s great to have a mix of stocks in your portfolio. There are all sorts of sizes and flavors of stocks from which ...... Read Full Article

Horizon Therapeutics plc - Rule 2.12 Announcement

Wed, 01 Mar 2023 21:05:00 DUBLIN, March 01, 2023--In accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the "Irish Takeover Rules"), Horizon confirms that, as of the close of business on February 23, 2023, Horizon’s issued ordinary share capital is comprised of 228,832,390 ordinary shares, ...... Read Full Article

Horizon Therapeutics plc Reports Fourth-Quarter and Full-Year 2022 Financial Results

Wed, 01 Mar 2023 12:02:00 DUBLIN, March 01, 2023--Horizon Therapeutics plc Reports Fourth-Quarter and Full-Year 2022 Financial Results... Read Full Article

Horizon Therapeutics plc Opens Applications for #RAREis Global Advocate Grant Program

Tue, 28 Feb 2023 13:00:00 DUBLIN, February 28, 2023--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that applications for its 2023 #RAREis Global Advocate Grant are open through March 31, 2023. To increase impact and support advocates who are catalysts for rare disease community needs, #RAREis will grant 50 groups with ...... Read Full Article

Horizon Therapeutics plc Announces Voting Results from Special Shareholder Meetings

Fri, 24 Feb 2023 21:05:00 DUBLIN, February 24, 2023--Horizon Therapeutics plc (NASDAQ: HZNP):... Read Full Article

New Data Suggest UPLIZNA® (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) Did Not Increase the Risk of COVID-19 Infection or Reduce Antibody Levels From Childhood Vaccines

Thu, 23 Feb 2023 13:00:00 DUBLIN, February 23, 2023--New data suggest UPLIZNA (inebilizumab-cdon) didn't increase the risk of COVID-19 infection or reduce antibody levels from childhood vaccines in NMOSD... Read Full Article

Horizon Therapeutics Public Limited Company (HZNP) Shares Got Re-Rated Due to Acquisition Announcement

Thu, 23 Feb 2023 07:18:25 ClearBridge Investments, an investment management company, released its “ClearBridge Select Strategy” fourth quarter 2022 investor letter. A copy of the same can be downloaded here. The strategy outperformed its benchmark, the Russell 3000 Index, in the fourth quarter. On an absolute basis, ...... Read Full Article

Soros buys Horizon Therapeutics, First Horizon, adds to Alphabet, cuts Amazon

Tue, 14 Feb 2023 04:42:52 By Daniel Shvartsman... Read Full Article

Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2022 Financial Results on March 1, 2023

Mon, 30 Jan 2023 13:00:00 DUBLIN, January 30, 2023--Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it will release its fourth-quarter and full-year 2022 financial results on Wednesday, March 1, 2023, prior to the open of U.S. financial markets.... Read Full Article

Rule 15 (c) Announcement – Horizon Therapeutics plc

Fri, 27 Jan 2023 21:05:00 DUBLIN, January 27, 2023--Horizon Therapeutics plc (NASDAQ: HZNP):... Read Full Article

Rule 17 (b) Announcement – Horizon Therapeutics plc

Mon, 23 Jan 2023 23:05:00 DUBLIN, January 23, 2023--Horizon Therapeutics plc (NASDAQ: HZNP):... Read Full Article

Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint in the Second Study Population; Only Phase 2 Trial to Meet Primary Endpoint in Both Patient Populations

Wed, 18 Jan 2023 13:00:00 DUBLIN, January 18, 2023--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the primary endpoint was met for the second population in its Phase 2 clinical trial evaluating dazodalibep for the treatment of Sjögren’s syndrome. The Phase 2 trial evaluated two patient ...... Read Full Article

Here’s Why Horizon Therapeutics Public Limited Company (HZNP) Surged in Q4

Tue, 17 Jan 2023 12:08:21 Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Mid Cap Growth Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, the mid-cap stocks posted solid gains. On the ...... Read Full Article

Rule 2.12 Announcement – Horizon Therapeutics plc

Thu, 12 Jan 2023 22:05:00 DUBLIN, January 12, 2023--In accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the "Irish Takeover Rules"), Horizon confirms that, as of the close of business on January 11, 2023, Horizon’s issued ordinary share capital is comprised of 228,768,464 ordinary shares, ...... Read Full Article

Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Discoid Lupus Erythematosus

Wed, 04 Jan 2023 13:00:00 DUBLIN, January 04, 2023--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a Phase 2, randomized, placebo-controlled trial to evaluate its development-stage medicine daxdilimab, a potentially first-in-class, fully human monoclonal antibody targeting anti-ILT7 depletes certain dendritic cells to ...... Read Full Article
<